Global Custom Market Research Reports Provider Company

phone

Ovarian Cancer - Pipeline Review, H2 2017

  • Published Date: 29 Dec 2017
  • Number of Pages: 2232
  • Category: Healthcare and Medical
  • Country: Global
Ovarian Cancer - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H2 2017, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 14, 141, 144, 7, 221, 26 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 12, 45 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct
Table of Contents
Table of Contents 2
Introduction 12
Ovarian Cancer - Overview 13
Ovarian Cancer - Therapeutics Development 14
Ovarian Cancer - Therapeutics Assessment 77
Ovarian Cancer - Companies Involved in Therapeutics Development 111
Ovarian Cancer - Drug Profiles 242
Ovarian Cancer - Dormant Projects 2130
Ovarian Cancer - Discontinued Products 2152
Ovarian Cancer - Product Development Milestones 2157
Appendix 2169

List Of Tables


Number of Products under Development for Ovarian Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H2 2017
Ovarian Cancer - Pipeline by 4SC AG, H2 2017
Ovarian Cancer - Pipeline by AB Science SA, H2 2017
Ovarian Cancer - Pipeline by AbbVie Inc, H2 2017
Ovarian Cancer - Pipeline by AbGenomics International Inc, H2 2017
Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017
Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2017
Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H2 2017
Ovarian Cancer - Pipeline by Advantagene Inc, H2 2017
Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H2 2017
Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2017
Ovarian Cancer - Pipeline by AlfaSigma SpA, H2 2017
Ovarian Cancer - Pipeline by Alkermes Plc, H2 2017
Ovarian Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2017
Ovarian Cancer - Pipeline by Almac Discovery Ltd, H2 2017
Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H2 2017
Ovarian Cancer - Pipeline by Alteogen Inc, H2 2017
Ovarian Cancer - Pipeline by Altor BioScience Corp, H2 2017
Ovarian Cancer - Pipeline by Ambrx Inc, H2 2017
Ovarian Cancer - Pipeline by Amgen Inc, H2 2017
Ovarian Cancer - Pipeline by Amunix Operating Inc, H2 2017
Ovarian Cancer - Pipeline by Anavex Life Sciences Corp, H2 2017
Ovarian Cancer - Pipeline by ANP Technologies Inc, H2 2017
Ovarian Cancer - Pipeline by AntiCancer Inc, H2 2017
Ovarian Cancer - Pipeline by Antigen Express Inc, H2 2017
Ovarian Cancer - Pipeline by Antoxis Ltd, H2 2017
Ovarian Cancer - Pipeline by Aphios Corp, H2 2017
Ovarian Cancer - Pipeline by Aposense Ltd, H2 2017
Ovarian Cancer - Pipeline by Aprea AB, H2 2017
Ovarian Cancer - Pipeline by arGEN-X BV, H2 2017
Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H2 2017
Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H2 2017
Ovarian Cancer - Pipeline by ArQule Inc, H2 2017
Ovarian Cancer - Pipeline by Array BioPharma Inc, H2 2017
Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2017
Ovarian Cancer - Pipeline by Astellas Pharma Inc, H2 2017
Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2017
Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2017
Ovarian Cancer - Pipeline by Athenex Inc, H2 2017
Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2017
Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2017
Ovarian Cancer - Pipeline by Bayer AG, H2 2017
Ovarian Cancer - Pipeline by BeiGene Ltd, H2 2017
Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H2 2017
Ovarian Cancer - Pipeline by BioCancell Ltd, H2 2017
Ovarian Cancer - Pipeline by BioMoti Ltd, H2 2017
Ovarian Cancer - Pipeline by Bionomics Ltd, H2 2017
Ovarian Cancer - Pipeline by BioNTech AG, H2 2017
Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2017
Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Ovarian Cancer - Pipeline by Boston Biomedical Inc, H2 2017
Ovarian Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Ovarian Cancer - Pipeline by Caladrius Biosciences Inc, H2 2017
Ovarian Cancer - Pipeline by Calithera Biosciences Inc, H2 2017
Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2017
Ovarian Cancer - Pipeline by Cavion LLC, H2 2017
Ovarian Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Ovarian Cancer - Pipeline by Celgene Corp, H2 2017
Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
Ovarian Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2017
Ovarian Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2017

List Of Figures


Number of Products under Development for Ovarian Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

The global market size of Ovarian Cancer Drugs is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the

View Report

Polycystic Ovarian Syndrome - Pipeline Review, H1 2018. Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H1 2018, provides an overview of the

View Report

Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2017 GlobalDatas clinical trial report, Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2017 provides an overview of Metastatic Ovarian Cancer clinical trials

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports